Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mitoxantrone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 2/20 | 0.86 |
| ▸ | MEN1 | O00255 | 4/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.86 |
| ▸ | BLM | P54132 | 3/20 | 0.86 |
| ▸ | LMNA | P02545 | 3/20 | 0.86 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.86 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.86 |
| ▸ | NSD2 | O96028 | 3/20 | 0.86 |
| ▸ | NPC1 | O15118 | 3/20 | 0.86 |
| ▸ | RAB9A | P51151 | 3/20 | 0.86 |
| ▸ | USP2 | O75604 | 2/20 | 0.86 |
| ▸ | TP53 | P04637 | 2/20 | 0.86 |
| ▸ | RECQL | P46063 | 2/20 | 0.86 |
| ▸ | MTOR | P42345 | 2/20 | 0.86 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.86 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.86 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.86 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.86 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitoxantrone SCHEMBL31237733 | 1.00 | MEN1 (0.86) | MEN1KMT2ABLMLMNAMAPK1 | |
| Mitoxantrone SCHEMBL31060880 | 1.00 | MEN1 (0.86) | MEN1KMT2ABLMLMNAMAPK1 | |
| Mitoxantrone SCHEMBL21874585 | 0.93 | MEN1 (0.89) | MEN1KMT2ABLMLMNAMAPK1 | |
| SCHEMBL11391594 | 0.93 | MEN1 (1.00) | MEN1KMT2ABLMLMNAMAPK1 | |
| Mitoxantrone SCHEMBL20214110 | 0.93 | MEN1 (1.00) | MEN1KMT2ABLMLMNAMAPK1 | |
| SCHEMBL11041207 | 0.93 | MEN1 (1.00) | MEN1KMT2ABLMLMNAMAPK1 | |
| Mitoxantrone SCHEMBL3000 | 0.93 | MEN1 (1.00) | MEN1KMT2ABLMLMNAMAPK1 | |
| SCHEMBL11517949 | 0.93 | MEN1 (1.00) | MEN1KMT2ABLMLMNAMAPK1 | |
| SCHEMBL11036806 | 0.93 | MEN1 (1.00) | MEN1KMT2ABLMLMNAMAPK1 | |
| Mitoxantrone SCHEMBL29720597 | 0.93 | MEN1 (1.00) | MEN1KMT2ABLMLMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321009-A1 | USE OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING BREAST CANCER | SHENZHEN CHINA RESOURCES JIUCHUANG MEDICAL AND PHARMACEUTICAL CO., LTD (CN) | 2023-10-12 | — | — | US | claimed |
| US-20230201378-A1 | APPLICATION OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING DISEASE RELATED TO THYROIDECTOMY | SHENZHEN CHINA RESOURCES JIUCHUANG MEDICAL AND PHARMACEUTICAL CO., LTD (CN) | 2023-06-29 | — | — | US | claimed |
| EP-4190364-A1 | USE OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING BREAST CANCER | Shenzhen China Resources Jiuchuang Medical and Pharmaceutical Co., Ltd (CN) | 2023-06-07 | — | — | EP | claimed |
| EP-4159244-A1 | APPLICATION OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING DISEASE RELATED TO THYROIDECTOMY | Shenzhen China Resources Jiuchuang Medical and Pharmaceutical Co., Ltd (CN) | 2023-04-05 | — | — | EP | claimed |
| CN-114569544-A | Preparation method of mitoxantrone injection | 深圳华润九创医药有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114569545-A | Stable mitoxantrone preparation | 深圳华润九创医药有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114053436-A | Application of mitoxantrone preparation in preparation of medicine for diagnosing and treating breast cancer | 深圳华润九创医药有限公司 | 2022-02-18 | — | — | CN | claimed |
| WO-2022021906-A1 | USE OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING BREAST CANCER | 深圳华润九创医药有限公司 | 2022-02-03 | — | — | WO | claimed |
| CN-113730603-A | Application of mitoxantrone preparation in preparation of medicine for treating thyroidectomy-related diseases | 深圳华润九创医药有限公司 | 2021-12-03 | — | — | CN | claimed |
| WO-2021238367-A1 | APPLICATION OF MITOXANTRONE PREPARATION IN PREPARATION OF DRUG FOR DIAGNOSING AND TREATING DISEASE RELATED TO THYROIDECTOMY | 深圳华润九创医药有限公司 | 2021-12-02 | — | — | WO | claimed |
| EP-3112368-A1 | PURINONE DERIVATIVE AS BTK KINASE INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-01-04 | — | — | EP | claimed |
| EP-2424513-B1 | QUINONE DERIVATIVE 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE FOR THE TREATMENT OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | SANTHERA PHARMACEUTICALS CH (CH) | 2015-05-20 | — | — | EP | claimed |
| EP-2424513-A1 | QUINONE DERIVATIVE 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE FOR THE TREATMENT OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2012-03-07 | — | — | EP | claimed |
| WO-2010124713-A1 | QUINONE DERIVATIVE 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE FOR THE TREATMENT OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-11-04 | — | — | WO | claimed |
| EP-2246048-A1 | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-11-03 | — | — | EP | claimed |
| US-20250197401-A1 | PURINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-19 | — | — | US | disclosed |
| CN-119733053-A | Pharmaceutical combination of KRAS G12C inhibitor and mitoxantrone and application thereof | 福建医科大学附属协和医院 | 2025-04-01 | — | — | CN | disclosed |
| US-20100280130-A1 | QUINONE DERIVATIVE 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE FOR THE TREATMENT OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-11-04 | — | — | US | disclosed |
| WO-2010124713-A1 | QUINONE DERIVATIVE 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE FOR THE TREATMENT OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-11-04 | — | — | WO | disclosed |
| EP-2246048-A1 | Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280130-A1 | QUINONE DERIVATIVE 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE FOR THE TREATMENT OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS | NDUFB5, NDUFB7, NDUFB10 | TOP2A 780/4885MEN1 3140/4885KMT2A 1848/4885 |
| US-20250197401-A1 | PURINONE DERIVATIVE | BTK, KIT, SYK | TOP2A 1892/4885MEN1 3212/4885KMT2A 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.